Original Article

Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma: a meta-analysis

Xueping Zhou*, Zhaohui Tang*, Jiandong Wang, Peiyi Lin, Zhisheng Chen, Lisheng Lv, Zhiwei Quan, Yingbin Liu

Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200092, China. *Equal contributors.

Received September 4, 2014; Accepted October 13, 2014; Epub November 15, 2014; Published November 30, 2014

Abstract: Objective: We conducted a meta-analysis to evaluate the efficacy and toxicity of DEB-TACE in the treatment of patients with intermediate-stage HCC. Methods: Studies published in PubMed, Embase and Web of Science, were systematically reviewed to identify those that assessed the efficacy and toxicity of DEB-TACE in the treatment of patients with HCC. Hazard ratio, risk ratio and 95% confidence intervals were calculated, using a fixed-effects model or a random-effects model. Results: Nine studies with a total of 830 patients met the inclusion criteria were included in this study. DEB-TACE significantly improved overall survival and progression free survival, and also increased objective response rate and disease control rate. However, in subgroup analyses, pooled results showed that, the survival benefits of DEB-TACE were not found in the randomized controlled trials, but were observed in Non-RCTs. The incidence of most common adverse events, including nausea, pain, fever, and fatigue, was not significant difference between the DEB-TACE group and conventional TACE group. Conclusions: Despite DEB-TACE significantly prolonged the survival and response rate in the patients with HCC, the conclusion about the survival benefits should be interpreted with caution, since these findings were only found in retrospective Non-RCTs, and not in prospective RCTs.

Keywords: DEB-TACE, hepatocellular carcinoma, efficacy, toxicity, meta-analysis

Introduction

Hepatocellular carcinoma (HCC) is the sixth most common cancer with an increasing incidence worldwide, and is the third most common cause of cancer-related death worldwide [1, 2]. Despite curative therapies, such as liver transplantation, surgical resection, and radio-frequency ablation (RFA) are applied in patients with HCC, only less than 20% of HCC patients are eligible for these treatment options [3, 4].

Transarterial chemoembolization (TACE) is widely used in the patients who are not suitable for curative treatments [5, 6]. It involves the injection of chemotherapeutic agent, mixed with selective vascular embolization, both of which are delivered to the arterial of tumor. The slow release of these agents would result in a higher intratumor concentrations, and then occlude the blood vessel causing infarction and necrosis [7]. In the previous studies, TACE has been reported to have an improvement in partial response, as well as a delay in tumor progression and vascular invasion [8-11]. However, the post-TACE complications, such as acute liver or renal failure, encephalopathy, and upper gastrointestinal bleeding, seems to be severe [12]. Therefore, there is a requirement for treatment regimens, which would improve the response rate and survival, as well as reduce the TACE-associated complications.

The drug-eluting beads (DC bead, Biocompatibles UK Ltd) is a novel drug delivery embolization system, which has been developed to deliver higher dose of chemotherapeutic agent and to prolong the time of contact time with
DEB-TACE of hepatocellular carcinoma

Results from the preclinical and clinical trials have shown that in the HCC patients, TACE with DC Bead has a higher intra-tumor concentration and lower systemic concentration of doxorubicin, compared with intra-arterial doxorubicin and conventional TACE (cTACE) [15, 16]. Phase/I/II studies also have indicated that patients treated with doxorubicin-eluting beads TACE (DEB-TACE) have a prolonged survival and low toxicity [15-18]. However, in a recently published meta-analysis [19], the pooled results showed that DEB-TACE did not increase the response rate in the HCC patients, when compared with cTACE. This controversial result raised the concern that DEB-TACE may not be so promising in improving patients' response rate. Thus, we conduct an updated meta-analysis to re-evaluate the efficacy and safety of DEB-TACE in the treatment of HCC.

Methods

Literature search and inclusion criteria

We included studies in all languages when the following inclusion criteria were met: (1) eligible patients were ≥ 18 years older with a diagnosis of HCC; (2) patients in the experimental group treated by TACE with DC Bead loaded with doxorubicin, while patients in the control group received other type of therapy; (3) the studies provided data of interest, including overall survival (OS), progression free survival (PFS), objective response rate (ORR), disease control rate (DCR) and adverse events.

Data extraction and quality assessment

Two reviewers (Xueping Zhou and Zhaohui Tang) independently extracted data from the studies included using a standardized Excel file. Data as follows were recorded: first author, year of publication, number of patients, the mean age, treatment regimen, performance status, OS, PFS, and adverse events. Any disagreement was resolved by discussion and consensus.

The methodological quality of randomized controlled trials (RCTs) was assessed by the Jadad scale [20]. The scale consists of three items, which describe randomization (0-2 points), blinding (0-2 points), and dropouts and withdraws (0-1 point). The scale ranges from 0 to 5 points, and higher scores indicate better reporting. A score of 1 is obtained when each of points described is met. And another point is given when the method of randomization and/
## Table 1. Baseline Characteristics of the included studies

<table>
<thead>
<tr>
<th>Total (830)</th>
<th>Treatment</th>
<th>Median age (range)</th>
<th>Male/ Female</th>
<th>Child-Pugh Class</th>
<th>ECOG PS</th>
<th>Etiology of cirrhosis</th>
<th>Study design</th>
<th>Jada scale</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lammer J [32] (201)</td>
<td>DEB-TACE</td>
<td>67.3 ± 9.1</td>
<td>79/14</td>
<td>A/B: 77/16</td>
<td>PS 0/1: 74/19</td>
<td>HCV/HBV/alcohol: 22/16/43</td>
<td>RCT</td>
<td>4</td>
</tr>
<tr>
<td>cTACE</td>
<td>67.4 ± 8.8</td>
<td>95/13</td>
<td>A/B: 89/19</td>
<td>PS 0/1: 80/28</td>
<td>HCV/HBV/alcohol: 18/18/57</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MABED M [33] (100)</td>
<td>DEB-TACE</td>
<td>52 (36-60)</td>
<td>32/18</td>
<td>A/B: 34/16</td>
<td>PS 0/1: 13/37</td>
<td>HBV/HCV: 5/37</td>
<td>RCT</td>
<td>3</td>
</tr>
<tr>
<td>Intravenous doxorubicin</td>
<td>51 (34-60)</td>
<td>33/17</td>
<td>A/B: 35/15</td>
<td>PS 0/1: 15/35</td>
<td>HBV/HCV: 8/35</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recchia F [34] (105)</td>
<td>DEB-TACE</td>
<td>72 (53-80)</td>
<td>25/10</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>Prospective case-control</td>
<td>None</td>
</tr>
<tr>
<td>cTACE</td>
<td>70.0 (47-80)</td>
<td>50/20</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malagari K [35] (41)</td>
<td>DEB-TACE</td>
<td>70.7 (6.9)</td>
<td>31/10</td>
<td>A/B: 23/18</td>
<td>PS 0/1: 26/15</td>
<td>NR</td>
<td>RCT</td>
<td>3</td>
</tr>
<tr>
<td>Intravenous doxorubicin</td>
<td>70 (7.9)</td>
<td>34/9</td>
<td>A/B: 26/17</td>
<td>PS 0/1: 28/15</td>
<td>NR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ferrer Puchol M.D. [36] (72)</td>
<td>DEB-TACE</td>
<td>68.4 ± 8.54</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>RCT</td>
<td>3</td>
</tr>
<tr>
<td>cTACE</td>
<td>69.26 ± 11.80</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dhanasekaran R [37] (71)</td>
<td>DEB-TACE</td>
<td>59.96 (11.45)</td>
<td>35/10</td>
<td>A/B/C: 22/11/12</td>
<td>NR</td>
<td>HCV/HBV/alcohol: 20/5/7</td>
<td>Retrospective case-control</td>
<td>None</td>
</tr>
<tr>
<td>cTACE</td>
<td>58.96 (13.3)</td>
<td>19/7</td>
<td>A/B/C: 11/11/4</td>
<td>NR</td>
<td>HCV/HBV/alcohol: 11/3/3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sacco R [38] (67)</td>
<td>DEB-TACE</td>
<td>71.3 ± 7.2</td>
<td>23/10</td>
<td>A/B: 29/4</td>
<td>NR</td>
<td>HCV/HBV/other: 22/4/7</td>
<td>RCT</td>
<td>4</td>
</tr>
<tr>
<td>cTACE</td>
<td>68.7 ± 8.1</td>
<td>22/12</td>
<td>A/B: 25/9</td>
<td>NR</td>
<td>HCV/HBV/other: 25/4/5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Song MJ [39] (129)</td>
<td>DEB-TACE</td>
<td>61.7 ± 9.8</td>
<td>42/18</td>
<td>A/B: 56/4</td>
<td>NR</td>
<td>HCV/HBV/alcohol: 8/4/4</td>
<td>Retrospective cohort</td>
<td>None</td>
</tr>
<tr>
<td>cTACE</td>
<td>59.4 ± 11.2</td>
<td>48/21</td>
<td>A/B: 62/6</td>
<td>NR</td>
<td>HCV/HBV/alcohol: 8/4/12</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wiggermann P [40] (44)</td>
<td>DEB-TACE</td>
<td>70.32 ± 7.06</td>
<td>18/4</td>
<td>A: 22</td>
<td>NR</td>
<td>Hepatitis/alcohol/other: 6/2/14</td>
<td>Retrospective case-control</td>
<td>None</td>
</tr>
<tr>
<td>cTACE</td>
<td>67.72 ± 9.02</td>
<td>19/3</td>
<td>A: 22</td>
<td>NR</td>
<td>Hepatitis/alcohol/other: 3/7/12</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: DEB-TACE, doxorubicin-eluting bead transarterial chemoembolization; cTACE, conventional TACE; NR, not report.
Statistical analyses

We assessed the efficacy of DEB-TACE in the treatment of HCC based on the data from the studies included. For time-to-event variable, such as OS and OS, hazard ratio (HR) with 95% confidence intervals (CIs) were directly extracted or calculated by a calculation sheet as previously described [22]. For dichotomous variables, such as ORR and adverse events, the number of patients with the events of interest and the total number of patients were extracted. And the risk ratio (RR) with 95% CI was calculated. Statistical heterogeneity was assessed using Cochran Q test and I² statistics [23]. The P value of Q test < 0.1 or I² > 50% are considered to have heterogeneity among the included studies. A random-effects model (DerSimonian and Laird method) [24] was applied to pool the estimates when the heterogeneity existed, otherwise, a fixed-effects model (Mantel-Haenszel method) [25] was used. In the presence of heterogeneity, sensitivity analyses based on different study design, and sample size were conducted to explore the potential sources. Publication bias was assessed by Begg and Egger's test [26, 27]. A P value less than 0.05 was judged as statistically significant, except where otherwise specified. Statistical analyses were performed by using STATA version 12.0 (Stata Corporation, College Station, TX, USA).

Results

Identification of eligible studies

The search strategy identified 767 potential studies from PubMed, Embase, and Web of Science. Of these, 167 were excluded because they were duplicate records, 483 were excluded after the titles and abstracts review, mainly because they were reviews, comment, academic meeting abstracts, or un-related with our topics, leaving 117 for full text screening. In the review, four trials were excluded for the following reasons: three studies with unavailable data for analysis [28-30], and one study with a single-arm design [31]. Finally, nine studies [32-40] with a total of 830 patients were included in this meta-analysis. The detailed flowchart of search strategy was shown in Figure 1.

Study characteristics and quality assessment

The main characteristics of five RCTs and four Non-RCTs were presented in Table 1. These studies were published from 2008 to 2012. The sample size ranged from 41 to 201 (total 830). Five studies were prospective RCTs and four were prospective or retrospective Non-RCTs. The predominant reasons for etiology of cirrhosis were hepatitis C virus infection (HCV) (36.3%), hepatitis B virus infection (HBV) (27.1%), and alcohol consumption (25.9%). Approximately 82.2% of patients were rated as Child-Pugh Class A or B, indicating intermediate-stage HCC. The ORR was defined as complete response (CR) plus partial response (PR), and DCR as ORR plus stable disease (SD). Among the patients in the DEB-TACE group, DEB chemoembolization was performed using DC beads loaded with 50-75 mg of doxorubicin in each trial. The median Jadad scale of the included studies was 3 (range from 3 to 4).

OS

Seven studies reported data of OS [33, 34, 36-40]. The aggregated results showed that DEB-TACE significantly improved OS in the treatment of HCC patients when compared with cTACE (HR = 0.67, 95% CI: 0.49, 0.91; Z = 2.56, P = 0.010) (Figure 2). The test for heterogeneity was not significant (Z = 0.00, P = 1.000). We also performed subgroup analyses based on different study design. Pooled estimates from five prospective RCTs showed that DEB-TACE did not significantly prolong OS when compared with cTACE (HR = 0.81, 95% CI: 0.52, 1.24; Z = 0.97, P = 0.330) (Figure 2). While, in the three Non-RCTs, the pooled results suggested that DEB-TACE had an improvement in OS (HR = 0.55, 95% CI: 0.35, 0.85; Z = 2.66, P = 0.008) (Figure 2). The Begg's and Egger's test indicated no existence of publication bias (for Begg's test, Z = 0.30, P = 0.764; for Egger's test, t = -0.60, P = 0.575) (Figure 3).

PFS

Three RCTs and one Non-RCT reported data of PFS [33, 34, 38, 39]. The pooled results of these studies indicated that DEB-TACE significantly prolonged PFS when compared with
Figure 2. Meta-analysis exploring the effect of DEB-TACE on overall survival.

Figure 3. Test for publication bias for HR of overall survival.
DEB-TACE of hepatocellular carcinoma

Figure 4. Meta-analysis exploring the effect of DEB-TACE on progression-free survival.

Figure 5. Meta-analysis exploring the effect of DEB-TACE on objective response rate.
cTACE (HR = 0.64, 95% CI: 0.47, 0.86; Z = 2.97, P = 0.003) (Figure 4). The test for heterogeneity was not significant (P = 0.588, I^2 = 0.0%).

In the subgroup analyses, pooled results from three RCTs showed that no significant benefit in PFS was observed for patients with HCC (HR = 0.72, 95% CI: 0.50, 1.05; Z = 1.69, P = 0.091) (Figure 4), following treatment with DEB-TACE. Since only one Non-RCT reported data of PFS, we did not perform the subgroup analysis of Non-RCT. The Begg’s and Egger’s test indicated no existence of publication bias (for Begg’s test, Z = 0.34, P = 0.734; for Egger’s test, t = 1.35, P = 0.310).

**ORR**

Six studies reported data of ORR [32, 33, 35, 36, 39, 40]. The pooled results suggested that patients with HCC under the treatment of DEB-TACE had a higher ORR when compared with those treated with cTACE (RR = 1.43, 95% CI: 1.20, 1.72; Z = 3.92, P = 0.000) (Figure 5). The test for heterogeneity was not significant (P = 0.275, I^2 = 21.1%).

In the subgroup analyses, a significantly high ORR was observed in patients in both of the RCTs (RR = 1.39, 95% CI: 1.06, 1.82; Z = 2.40, P = 0.016) and Non-RCTs (RR = 1.48, 95% CI: 1.17, 1.88; Z = 3.24, P = 0.001).

**DCR**

Five studies reported data of DCR [32, 33, 35, 39, 40]. The pooled results showed that patients with HCC under the treatment of DEB-TACE had a higher DCR when compared with those treated with cTACE (RR = 1.29, 95% CI: 1.14, 1.46; Z = 4.05, P = 0.000) (Figure 6). The test for heterogeneity was not significant (P = 0.379, I^2 = 4.9%).

In the subgroup analyses, a significantly high DCR was observed in patients in both of the RCTs (RR = 1.33, 95% CI: 1.09, 1.61; Z = 2.84, P = 0.004) and Non-RCTs (RR = 1.24, 95% CI: 1.10, 1.40; Z = 3.44, P = 0.001) (Figure 6).

**Adverse events**

Eight prospective RCTs and Non-RCTs reported adverse events [32-38, 39, 40], but only six studies provided available data for analysis [32, 35-37, 39, 40]. The most common adverse events were post-embolization complications, including nausea, pain, fever, and fatigue. The pooled results showed that the incidence of adverse events were not significantly difference between the two groups (RR = 0.73, 95% CI: 0.37, 1.46; Z = 0.89, P = 0.374) (Figure 7).

**Discussion**

The major purpose of this meta-analysis was to update and re-evaluate the efficacy and safety of DEB-TACE in patients with HCC. This meta-analysis was performed based on five RCTs and four retrospective cohort or case-control studies. Our results suggest that DEB-TACE significantly improved the OS (HR = 0.67, 95% CI: 0.49, 0.91; Z = 2.56, P = 0.010) and PFS (HR = 0.64, 95% CI: 0.47, 0.86; Z = 2.97, P = 0.330), and also increased ORR (RR = 1.39, 95% CI: 1.06, 1.82; Z = 3.92, P = 0.000) and DCR (RR = 1.33, 95% CI: 1.09, 1.61; Z = 4.05, P = 0.000), compared with cTACE. However, in the subgroup analysis based on different study design, the survival benefit of DEB-TACE was not observed in the prospective RCTs, whereas was found in the retrospective studies. The adverse events in the two groups were not significantly difference.

Two meta-analysis exploring the effect of DEB-TACE in patients with HCC were published in 2013 [19] and 2014 [41]. In the study of Sheng Gao [19], the pooled estimates of odds ratios (OR) showed that there were no significantly difference in the CR, PR, SD, and OR between the DEB-TACE group and cTACE group. In the study of Kaijun Huang [41], DEB-TACE provides significantly better tumor response compared with cTACE, in terms of one-year and 2-year survival. However, all the two published studies had limitations. First, Sheng Gao et al. [19] did not perform the quality assessment of the included studies, which were of low quality, resulting in bias. Second, both of the studies [19, 41] used OR instead of HR to estimate the pooled effect. HR, which takes into account the patient numbers, time of events and censored data, was the most appropriate parameter for time-to-event analysis [42].

cTACE is regarded as the first-line treatment for patients with inoperable and intermediate HCC. Although it has been used for several years, the response rates vary greatly between different trials. The DC Bead is a novel precise drug...
DEB-TACE of hepatocellular carcinoma

delivery embolization system. It has been designed to load drug onto microspheres. And then microspheres are injected into the tumor, slowly releasing drug over 14 days. The higher and more sustained release of drug would maximize the drug's effectiveness in terms of

Figure 6. Meta-analysis exploring the effect of DEB-TACE on disease control rate.

Figure 7. Meta-analysis exploring the risk ratio of adverse events in patients with HCC.
DEB-TACE of hepatocellular carcinoma

response [43]. In addition, the limited release of drug in the systemic circulation would reduce the drug's systemic toxicity [43]. Preclinical and clinical trials have indicated that doxorubicin reserved a higher and prolonged concentration within the tumor, and a lower concentration in the systemic circulation, after TACE with DC Bead was performed [44-46]. Thus, it is assumed that TACE with doxorubicin-loaded would have promising efficacy.

In this meta-analysis, the results suggested that HCC patients treated with DEB-TACE had significant improvement survival benefits in OS and PFS, compared with those treated with cTACE. However, these benefits were only found in patients from retrospective cohort or case-control studies, while patients from prospective RCTs did not seem to obtain these benefits. Despite the patients in the retrospective studies were stringently selected according rigorous criteria, and their baseline characteristics were well matched between the two groups, the selection bias was avoidable. Moreover, RCTs are scientifically the most rigorous method for evaluation of effectiveness of medical interventions, and their results were more reliable and valid. Thus, the survival benefits of DEB-TACE may not be so promising as it had been thought.

Despite our results indicated that the DEB-TACE treatment had no survival benefit in patients with HCC, some studies have obtained interesting outcomes in special subgroup population. In the prospective study conducted by M. Mabed et al. [33], the authors found that patients with serum albumin > 3.3 g/dL in the experimental group had a prolonged OS than those in the control group; the median OS in the two groups were 60 weeks and 36 weeks, respectively [33]. Similar results were also observed in another two studies conducted by O'Suilleabhain et al. [47] and Wigmore et al. [48]. And the authors assumed that serum albumin may be an independent prognostic factor for the better OS in HCC patients treated with DEB-TACE.

However, this study has several potential limitations. First, we admit that our meta-analysis included some studies, which had a relatively small sample size. Overestimation of the treatment effect is more likely in smaller trials compared with larger trials. Second, some of the included studies did not provide sufficient data of time-to-event outcomes for meta-analysis directly. In order to obtain these data, we extracted the HRs with 95% CI from the Kaplan-Meier curves, using Engauge Digitizer, which may lead to inaccurate data. Third, the targeted population varied greatly, such as the gender, ethnicity, and disease status. These factors may have a potential impact on our results.

In conclusion, this meta-analysis suggested that the treatment of DEB-TACE significantly improved OS and PFS, and also increased ORR and DCR, in the patients with HCC. However, the pooled results from RCTs showed that DEB-TACE did not have beneficial survival in the treatment of HCC patients. Thus, these results should be interpreted with caution. Given the limited number of RCTs and small sample size, additional larger scale RCTs are needed to confirm the current findings and investigate the prognostic factors for the beneficial survival in HCC patients treated with DEB-TACE.

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Xueping Zhou, Department of General Surgery, Xinhua Hospital, Affiliated to Shanghai Jiao Tong University, 1665 Kongjiang Rord, Shanghai 200092, China. Tel: +8602125077905; E-mail: zhouxueping_339@163.com

References

DEB-TACE of hepatocellular carcinoma


[16] Poon RT, Tso WK, Pang RW, Ng KK, Woo R, Tai KS, Fan ST. A phase I/II trial of chemoemboli-
DEB-TACE of hepatocellular carcinoma

zation with drug eluting beads: results from the PRECISION V randomized trial. Hepatology 2009; 50: 1079A.


